Skip to content

- locationPlaceholder

Choose your country or region

Global

Global
- English

North America

North America (Regional)
- English
Canada
- English
- Français
United States
- English

Asia Pacific

Asia Pacific (Regional)
- English
Australia
- English
China
- 中文
Hong Kong
- English
- 中文
Japan
- 日本
Korea
- 한국어
New Zealand
- English

Europe, Middle East & Africa (EMEA)

Latin America

Latin America (Regional)
- Español
Argentina
- Español
Bolivia
- Español
Brazil
- Português
Central America and the Caribbean
- Español
Chile
- Español
Colombia
- Español
Ecuador
- Español
Mexico
- Español
Paraguay
- Español
Peru
- Español
Uruguay
- Español

About us
- About us
- Our Credo
- Our responsibilities
- Our heritage
Our innovation
- Our innovation
- Focus areas
- Our products
- Clinical trials
How we work
- How we work
- Collaborations
- Policy
- Transparency
Careers
Newsroom

About us
- About us
- Our Credo
- Our responsibilities
- Our heritage
Our innovation
- Our innovation
- Focus areas
- Our products
- Clinical trials
How we work
- How we work
- Collaborations
- Policy
- Transparency
Careers
Newsroom

Search Query

Listening...

Search Results

No Results

See all results

Sorry, I don't understand. Please try again

EMEA Search Results

Search Query

Listening...

Dates

All (225)
2024 (60)
2023 (34)
2022 (7)

Types

All (225)
Article (2)
Page (59)
Press Release (164)

All (225)
2024 (60)
2023 (34)
2022 (7)

All (225)
Article (2)
Page (59)
Press Release (164)

Oncology

New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukaemia

Read more
Neuroscience

SPRAVATO®▼ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder

Read more
Immunology

New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients with Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life

Read more
Immunology

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical and Histologic Remission and Endoscopic Normalisation at Week 38

Read more
Immunology

TREMFYA®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study

Read more

About us
Our innovation
Get in touch
- Contact us
- Socials
  - linkedin
  - twitter
Key links

This site is published by Janssen Pharmaceutica N.V., which is solely responsible for its content. This site is intended for visitors in Europe, the Middle East and Africa, with the exception of users in the UK, who should use the Janssen UK site.
Notice of information on the protection of personal data - access to PMSI data / Notice d’information protection des données personnelles - accès aux données du PMSI.

© Janssen Pharmaceutica NV December 2026. Capitalised product names are trademarks of Johnson & Johnson or its affiliated companies. All third-party trademarks used herein are registered trademarks of their respective owners.
Last Updated: September 26, 2024